Lakefront Biotherapeutics NV current report, Q4 FY2019

Business Context and Reporting Period

This Form 6-K is filed by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of December 2019, specifically dated December 19, 2019. The filing serves to incorporate by reference a press release (Exhibit 99.1) issued on that date. The registrant is a foreign private issuer incorporated in Belgium, with its principal executive office in Mechelen.

Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to distribute a press release and does not contain a financial statement or quantitative performance data.

Material Changes

The filing does not detail material financial changes versus prior periods. The primary content is the incorporation of a press release, the specific details of which are not included in the provided text.

Guidance, Outlook, and Risks

The filing incorporates a press release by reference but does not explicitly state guidance, outlook, or specific risks within the body of the Form 6-K text provided. The text notes that quotes from Dr. Merdad Parsey and Dr. Walid Abi-Saab contained in the attached press release are not incorporated by reference into the Company's Registration Statements.

Key Facts for Investor Verification

  • Verify the actual company name: The filing is for Galapagos NV, despite metadata suggesting Lakefront Biotherapeutics NV.
  • Review Exhibit 99.1 (the press release) separately, as the core information regarding the December 19, 2019 event is contained there and not in the Form 6-K text itself.
  • Note that specific quotes from Dr. Merdad Parsey and Dr. Walid Abi-Saab in the press release are excluded from incorporation into the Company's Registration Statements.
  • Confirm the filing date of December 19, 2019, and the signature by Xavier Maes, Company Secretary.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.